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Abstract
Chronic obstructive pulmonary disease is characterised by oxidative stress, but little is known 
about the associations between antioxidant status and all-cause mortality in adults with this 
disease. The objective of the present study was to examine the prospective associations between 
concentrations of α- and β-carotene, β-cryptoxanthin, lutein/zeaxanthin, lycopene, Se, vitamin C 
and α-tocopherol and all-cause mortality among US adults with obstructive lung function. Data 
collected from 1492 adults aged 20–79 years with obstructive lung function in the National Health 
and Nutrition Examination Survey III (1988–94) were used. Through 2006, 629 deaths were 
identified during a median follow-up period of 14 years. After adjustment for demographic 
variables, the concentrations of the following antioxidants modelled as continuous variables were 
found to be inversely associated with all-cause mortality among adults with obstructive lung 
function: α-carotene (P=0.037); β-carotene (P=0.022); cryptoxanthin (P=0.022); lutein/zeaxanthin 
(P=0.004); total carotenoids (P=0.001); vitamin C (P<0.001). In maximally adjusted models, only 
the concentrations of lycopene (P=0.013) and vitamin C (P=0.046) were found to be significantly 
and inversely associated with all-cause mortality. No effect modification by sex was detected, but 
the association between lutein/zeaxanthin concentrations and all-cause mortality varied by 
smoking status (Pinteraction = 0.048). The concentrations of lycopene and vitamin C were inversely 
associated with all-cause mortality in this cohort of adults with obstructive lung function.
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Chronic obstructive pulmonary disease (COPD) remains a potent public health problem in 
the USA and globally(1,2). After decades of increased mortality from COPD in the USA, the 
rate of mortality has stabilised since 2000(3). Although the prevalence of smoking is the 
chief driver of the rate of mortality from COPD, identifying other factors that may influence 
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mortality and are amenable to interventions in individuals with COPD is of substantial 
interest.
Studies, mostly cross-sectional ones, have related nutritional factors including the intake of 
fruits and vegetables, which are rich sources of antioxidants, to pulmonary function and 
COPD(4–14). Dietary intakes of vitamin C(15–19), vitamin E(20,21), β-carotene(18,19,22) and 
carotenoids(21) have been linked to lung function. Furthermore, circulating concentrations of 
antioxidants including carotenoids, vitamin C, vitamin E and vitamin A have been linked to 
pulmonary function in cross-sectional studies(23–31) and to change in pulmonary function in 
prospective studies(32–34).
Assuming that adequate nutritional status may help to preserve lung function and that 
preserved lung function reduces mortality, adequate nutritional status might reduce mortality 
among people with impaired lung function. An ecological study has suggested that increased 
intakes of fruits and fish are inversely correlated with COPD mortality(35). Prospective 
studies have found that the intakes of fruits and vitamin E are inversely associated with 
mortality from COPD(36). Yet, little is known about the associations between antioxidant 
concentrations and mortality in adults with obstructive lung function. Oxidation is 
considered to be a key factor in the pathogenesis of COPD(37–39), but very little is known 
about the role of oxidation in and any possible beneficial effects of antioxidants on the 
prognosis of this disease. Therefore, the objective of the present study was to examine the 
associations between circulating concentrations of carotenoids (α-carotene, β-carotene, 
cryptoxanthin, lutein/zeaxanthin, and lycopene), vitamin C, vitamin E, and Se and all-cause 
mortality in a cohort of US adults with obstructive lung function.
Methods
The present study is based on data obtained from the Third National Health and Nutrition 
Examination Survey (NHANES III) Linked Mortality Study (baseline examination from 
1988 to 1994; mortality follow-up through 2006)(40,41). A complex sampling design 
(stratified multistage probability design) was used to select participants, who constituted a 
representative sample of the civilian non-institutionalised population in the USA. The 
participants were interviewed at their homes and extended an invitation to undergo an 
examination in the mobile examination centre, where they completed additional 
questionnaires, underwent a series of examinations, and provided blood and urine samples. 
The interview and examination response rates were 86 and 78 %, respectively. NHANES III 
received approval from the Institutional Review Board.
A probabilistic match of participants' information with the National Death Index death 
certificate records was conducted to identify deceased participants. If a match was not made, 
the participant was assumed to be alive at the end of the follow-up period. International 
Classification of Diseases-10 codes I00–I99 and C00–C97 were used to define deaths from 
circulatory disease and cancer, respectively.
Adults were eligible for a pulmonary function test without post-bronchodilator testing. The 
procedures used to conduct spirometry have been detailed elsewhere(42). The following 
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equations were used to calculate predicted forced expiratory volume in 1 s (FEV1) and 
forced vital capacity (FVC) in adults:
FEV1:
FVC:
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Mild obstructive impairment was defined as a FEV1/FVC <.70 and a FEV1 ≥80 %, 
moderate obstructive impairment was defined as a FEV1/FVC <0.70 and a FEV1 50 to <80 
% predicted, and severe obstructive impairment was defined as a FEV1/FVC <0.70 and a 
FEV1 <50 % predicted. Participants with mild, moderate or severe COPD were combined 
for analyses that examined associations between antioxidant concentrations and mortality 
risk.
The serum concentrations of five carotenoids (α-carotene, β-carotene, β-cryptoxanthin, 
lutein/zeaxanthin, and lycopene), vitamin C and α-tocopherol were measured using an 
isocratic reversed-phase HPLC. The serum concentrations of Se were measured using 
graphite furnace atomic absorption spectroscopy.
The following covariates were included in the analyses: age; sex; self-reported race or 
ethnicity (white, African American and other); educational level (<12, 12, or >12 years); 
smoking status; alcohol consumption; leisure-time physical activity; use of vitamin or 
mineral supplements; systolic blood pressure; HDL-cholesterol; non-HDL-cholesterol; BMI; 
C-reactive protein; urinary albumin:creatinine ratio; health status; histories of myocardial 
infarction and stroke; diabetes. Socio-demographic and lifestyle variables were included in 
the analyses because these variables are generally strongly associated with mortality. 
Furthermore, these variables are also associated with antioxidant concentrations. Lipid 
concentrations were included in the analyses because many of the antioxidants are lipid 
soluble. C-reactive protein as a marker of inflammation was included in the analyses 
because sources of inflammation can reduce antioxidant concentrations. Systolic blood 
pressure, BMI, urinary albumin:creatinine ratio, health status, diabetes, and histories of 
myocardial infarction and stroke were included in the analyses because these risk factors and 
conditions predict mortality and are associated with antioxidant concentrations.
Participants who reported that they had smoked at least 100 cigarettes during their lifetime 
and that they still smoke were designated as current smokers. Participants who reported that 
they had smoked at least 100 cigarettes during their lifetime and that they no longer smoke 
were designated as former smokers. Participants reporting not having smoked at least 100 
cigarettes were designated as never smokers. Using information from a FFQ, the frequency 
of alcohol consumption per month was estimated. Participants who engaged three or more 
times per week in an activity with a metabolic equivalent level ≥6 (for those aged ≥60 years) 
and with a metabolic equivalent ≥7 (for those aged <60 years) were considered to be 
vigorously active, participants who engaged five or more times per week in activities of 
which no more than two could be considered vigorous were considered to be moderately 
active, participants who engaged in activities that were not vigorous or moderate were 
considered to be lightly active, and participants who engaged in no leisure-time physical 
activity were considered to sedentary. Use of any vitamins or minerals by the participants 
was determined from the responses provided to the question `Have you taken any vitamins 
or minerals in the past month?'
The second and third systolic blood pressure measurements were averaged. BMI (kg/m2) 
was calculated from the measured weight and height. The concentrations of HDL-
cholesterol were measured on a Hitachi 704 analyser (Boehringer Mannheim Diagnostics) 
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after precipitation of other lipoproteins with a heparin–manganese chloride mixture. The 
concentrations of non-HDL-cholesterol were calculated by subtracting the concentration of 
HDL-cholesterol from that of total cholesterol. The serum concentrations of C-reactive 
protein were measured using latex-enhanced nephelometry on the Behring Nephelometer 
Analyzer System (Behring Diagnostics, Inc.). The urinary concentrations of albumin were 
measured using a fluorescent immunoassay on a Sequoia-Turner fluorometer (Sequoia-
Turner Corporation). The urinary concentrations of creatinine were measured from the rate 
of colour formation on a Beckman Synchron AS/ASTRA clinical analyser (Beckman 
Instruments, Inc.).
Participants with a history of myocardial infarction or stroke were identified from the 
responses provided to the questions `Has a doctor ever told you that you had a heart attack?' 
and `Has a doctor ever told you that you had a stroke?', respectively. Participants who 
provided a positive response to the question `Have you ever been told by a doctor that you 
have diabetes or sugar diabetes?' or had glycated Hb concentration ≥6.5% were considered 
to have diabetes.
Men and non-pregnant women aged 20–79 years who underwent a spirometric examination 
in the mobile examination centre and had reproducible FEV1 and FVC results were included 
in the analyses. Using the direct method, age adjustment was done to the projected year 
2000 US population for adults aged 20–79 years. Least-squares adjusted mean 
concentrations of antioxidants were calculated. Proportional-hazards analysis was used to 
estimate hazard ratios for antioxidants and mortality. In these multivariable models, 
antioxidants were modelled as continuous variables and again as quintiles calculated from 
the distributions of antioxidants among participants with obstructive lung function. To better 
approximate a normal distribution of several antioxidants, the following transformations 
were used in regression analyses: log transformation for β-carotene, lutein/zeaxanthin, 
lycopene, total carotenoids, and vitamin E and square root transformation for vitamin C. 
SAS (SAS Institute Inc.) and SUDAAN (Research Triangle Institute) were used to conduct 
statistical analyses.
Results
Of the 15 033 men and non-pregnant women aged 20–79 years who visited the mobile 
examination centre, 14 082 had reproducible FEV1 and FVC results. After exclusion of 
participants with an unreliable examination result, 13 134 remained. Of these participants, 
1746 had obstructive lung function and 12 168–12 516 participants had a measurement of 
the antioxidants. After exclusion of participants with missing study variables, the analytical 
sample size was reduced to 1492 participants with obstructive lung function.
The 1492 participants with obstructive lung function included 907 men, 585 women, 903 
whites, 315 African Americans, 232 Mexican Americans, and forty-two participants of 
another race or ethnicity. The mean and median ages were 55.7 and 58.0 years, respectively.
Among adults with obstructive lung function, 629 had died. The mean and median follow-up 
periods were 12.9 and 14.0 years, respectively. Differences in the means and percentages of 
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study variables between participants who died and those who remained alive among adults 
with obstructive lung function are given in Table 1. Decedents had lower age-adjusted mean 
concentrations of α-carotene, β-carotene, cryptoxanthin, lutein/zeaxanthin, and total 
carotenoids than survivors.
In age-adjusted regression models, the concentrations of all antioxidants, except Se, 
modelled as continuous variables were inversely associated with all-cause mortality (Table 
2). With progressive increasing levels of adjustment, the statistical significance of the hazard 
ratios for most antioxidants dwindled until only the concentrations of lycopene (P=0.013) 
and vitamin C (P=0.046) remained significantly and inversely associated with all-cause 
mortality in the maximally adjusted model (Table 2).
The concentrations of none of the antioxidants were significantly associated with mortality 
from circulatory diseases (Table 3). However, the concentrations of vitamin C were 
inversely associated with mortality from cancer. In addition, the concentrations of lutein/
zeaxanthin and lycopene were inversely associated with mortality from causes other than 
circulatory disease and cancer.
To examine the possibility of nonlinearity in the associations between antioxidant 
concentrations and all-cause mortality, a term for the squared concentrations of antioxidants 
was added to the proportional-hazards models, which proved to be statistically significant 
for lutein/zeaxanthin, total carotenoids, Se, vitamin C and vitamin E. Adjusted hazard ratios 
by quintiles of antioxidant concentrations are given in Table 4.
The associations between antioxidant concentrations and mortality did not vary by sex 
(Pinteractions >0.050). When possible interactions by race or ethnicity were examined, only 
the interaction term for lycopene was found to be statistically significant (Table 5). Except 
for β-carotene, the adjusted mean concentrations of antioxidants varied by race or ethnicity.
Detection for the presence of two-way interactions between antioxidant concentrations 
modelled as continuous variables and all-cause mortality was done. Significant interactions 
were found between the concentrations of vitamin E and those of β-carotene, cryptoxanthin, 
and lutein/zeaxanthin. Furthermore, significant interactions were found between the 
concentrations of lutein/zeaxanthin and those of cryptoxanthin and lycopene. When the 
concentration of each of the antioxidants was dichotomised using the median concentration 
and a four-level variable for each pair of antioxidants was created, none of the four-level 
variables was found to be a statistically significant predictor of mortality and, thus, shed 
little light on the interactions.
In general, antioxidant concentrations were lowest in participants who were current smokers 
and highest in participants who had never smoked (Table 6). Only the association between 
log-transformed lutein/zeaxanthin concentrations and all-cause mortality varied by smoking 
status (Pinteraction for continuous variable = 0.048). The maximally adjusted hazard ratios for 
continuous log-transformed concentrations were 0.62 (95% CI 0.46, 0.83) for current 
smokers, 1.03 (95% CI 0.71, 1.48) for former smokers, and 1.54 (95% CI 0.78, 3.04) for 
never smokers (Table 6). The concentrations of lutein/zeaxanthin, lycopene and total 
carotenoids were inversely associated with all-cause mortality in current smokers.
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Oxidation is a critical factor in the pathogenesis and pathophysiology of COPD(37–39). 
Although less clear, ongoing oxidative stress may exert a deleterious effect on the prognosis 
of those afflicted with this condition. If so, adequate antioxidant defences might be 
especially important for the welfare of people with COPD. The results of the present study 
showing that the concentrations of vitamin C and lycopene are inversely associated with all-
cause mortality in the study cohort with obstructive lung function provide measured support 
for this contention.
If the results of the present study do not represent chance findings, a couple of alternate 
explanations deserve consideration. First, vitamin C and lycopene may have in fact exerted 
beneficial effects in adults with obstructive lung function. Second, vitamin C and lycopene 
may represent risk markers for other factors that are responsible for the observed 
associations between the two antioxidants and mortality. Because fruits and vegetables are 
rich sources of both substances, one or more of the other compounds in fruits and vegetables 
may have been responsible for the observed associations. Along the same lines, antioxidants 
may represent markers for certain lifestyle characteristics that favourably affect mortality.
Prospective studies have reported that carotenoid concentrations are inversely associated 
with mortality(43–67), but not all studies have done so(52,68–70). These studies are supported 
by prospective studies of dietary or supplemental intakes of carotenoids(64,71–74), although 
other studies have failed to observe significant associations between antioxidant intake and 
mortality(70,75–78). Furthermore, in randomised trials of β-carotene, mortality was found to 
increase in the experimental group(77,79). However, we were unable to find studies that have 
examined whether antioxidant concentrations predict mortality in adults with obstructive 
lung function. Therefore, the results of the present study present novel information.
Evidence regarding the association between circulating concentrations of lycopene and 
mortality is mixed, with several studies providing supportive evidence(57,58,60,65) and others 
failing to do so(49,67,80). If lycopene reduces mortality, it is possible that COPD adults with 
higher lycopene concentrations would experience beneficial effects similar to those 
experienced by the population at large. The literature pertaining to the health effects of 
lycopene has zeroed in mostly on cancer(81). Of the carotenoids, the concentrations of 
lycopene had the strongest association with lung cancer(82), a condition to which adults with 
COPD are particularly susceptible given their smoking history. It is possible that lycopene 
may exert a favourable effect on all-cause mortality by reducing the risk of lung cancer. 
Adults with COPD are at an increased risk of mortality from CVD(83). Research has 
suggested that the intake and circulating concentrations of lycopene may be inversely 
associated with CVD(84–86). Besides being a strong singlet oxygen quencher(87), lycopene 
has been shown to affect endothelial function(88,89), HDL function(90), and matrix 
metalloproteinase-9 induction(91).
Whether the beneficial effects of adequate lycopene status specific to adults with COPD 
exist is less clear. Antioxidants including carotenoids, vitamin A and α-tocopherol have 
been demonstrated in lung tissue samples and bronchoalveolar lavage fluids(92,93), and 
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supplementation with β-carotene has been shown to lead to increases in β-carotene 
concentrations in cells of bronchoalveolar lavage fluids(94). As pointed out earlier, evidence 
points to inverse associations between intake and circulating concentrations of antioxidants 
and pulmonary function. In a trial of vegetable juice supplementation, young adults who 
received the vegetable juice rich in lycopene were found to experience significantly smaller 
reductions of FEV1 and FVC after a challenge with ozone compared with control 
participants(95). Such potential protection could be important in adults with COPD whose 
respiratory reserve capacity is compromised. Lycopene has also been found to limit the 
inflammatory response exhibited by airway epithelial cells after a challenge with rhinovirus 
infection(96). Because acute exacerbations of COPD due to respiratory infections result in 
excess mortality in adults with COPD, agents that could lessen the risk of respiratory 
infections or limit the damage caused by respiratory infections could possibly lead to 
reductions in mortality. However, a great deal of study is necessary to test the effects of 
antioxidant supplements on morbidity and mortality among adults with obstructive lung 
function.
Vitamin C, which is a water-soluble essential vitamin, is involved in numerous 
physiological processes critical to maintaining internal homeostasis of the human body. 
Besides acting as a cofactor in various enzymatic reactions, it serves as an important 
antioxidant scavenging both reactive oxygen species and reactive N species(97).
Observational prospective studies suggest that the intake and circulating concentrations of 
vitamin C are inversely associated with all-cause mortality or cause-specific mortality from 
leading chronic conditions(45–47,68,71,73,98–104). In other observational studies, however, 
vitamin C intake was found to have no apparent effect on mortality(52,62,75,78,105–107), and a 
systematic review concluded that supplementation with vitamin C has no beneficial effects 
on mortality(77). We are not aware of studies that have examined the effect of circulating 
concentrations of vitamin C on mortality among adults with obstructive lung function.
The prevalence of cigarette smoking is high among adults with obstructive lung function. In 
the present study, about 44 % of the participants reported being current smokers. 
Consequently, the excess mortality among adults with COPD is in part attributable to the 
high prevalence of smoking. Because smoking is a prime source of oxidative stress, 
bolstering antioxidant defences through supplementation with antioxidants could potentially 
mitigate some of the ravages from smoking-induced damage to the lungs and the 
downstream adverse effects of oxidative stress. It has been suggested by two large trials of 
supplementation with β-carotene and α-tocopherol in smokers and β-carotene and retinyl 
palmitate in participants who had been exposed to asbestos or were heavy smokers that 
yielded negative consequences for the experimental groups that caution needs to be 
exercised while extrapolating the findings of observational studies to recommendations for 
using antioxidant supplementation as an approach to primary or secondary 
prevention(108,109). The results of the present study did not show that the concentrations of 
β-carotene and vitamin E in current smokers were significantly associated with all-cause 
mortality.
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The results of the present study should be viewed in the context of several limitations. A 
larger sample size would have provided additional statistical power to detect significant 
associations, to examine the associations between antioxidant concentrations and mortality 
in separate groups of participants with mild, moderate, and severe obstructive lung function, 
and to examine associations between antioxidant concentrations and cause-specific 
mortality. The concentrations of antioxidants were measured at a single point in time and 
may not have represented the usual concentrations of the study participants. Concentration 
data of only α-tocopherol were available in NHANES III. Interest in the health effects of γ-
tocopherol has grown, and future investigations into the association between γ-tocopherol 
concentrations and mortality in adults with obstructive lung function would be of interest. 
Although a substantial number of covariates were included in the analyses, residual 
confounding remains a possibility as in most observational studies.
In conclusion, the concentrations of lycopene and vitamin C were inversely associated with 
all-cause mortality among adults with obstructive lung function. The failure of trials of β-
carotene and α-tocopherol supplementation in smokers to show benefits and of antioxidant 
supplementation in trials of secondary prevention suggest that caution needs to be exercised 
before recommending antioxidant supplementation in patients with COPD. Because limited 
studies have examined the associations between circulating concentrations of antioxidants 
and all-cause mortality and cause-specific mortality in adults with COPD, additional studies 
in this area are needed. In addition, studies examining the intake of antioxidants from diet 
and supplements in adults with COPD may also yield valuable data. Lastly, trials of 
antioxidant supplementation in patients with COPD may be needed to fully gauge the 
beneficial or harmful effects of antioxidant supplementation on complications from COPD. 
Regardless, physicians may evaluate the nutritional status of their patients with COPD and 
their diets and make recommendations consistent with current dietary recommendations.
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Table 1
Age-adjusted baseline means and percentages of study variables among adults aged 20–79 years with 
obstructive lung function, by mortality status, National Health and Nutrition Examination Survey III (1988–
94)
(Mean values or percentages with their standard errors)
Mortality status
Total (n 1492) Dead (n 629) Alive (n 863)
Mean SE Mean SE Mean SE P
Age (years) 55.7 0.7 65.8 0.7 50.5 0.8 <0.001
Education (years) 12.3 0.2 11.0 0.3 12.5 0.2 <0.001
No. of drinks (per month) 10.4 0.8 9.9 2.1 10.4 0.9 0.818
Systolic blood pressure (mmHg) 121.4 0.6 124.5 1.3 120.3 0.7 0.005
HDL-cholesterol (mmol/l) 1.3 0.0 1.1 0.1 1.3 0.0 0.015
Non-HDL-cholesterol (mmol/l) 4.1 0.1 4.2 0.1 4.1 0.0 0.291
BMI (kg/m2) 26.5 0.3 27.6 0.9 26.5 0.3 0.227
Albumin:creatinine ratio (mg/g) 17.8 1.4 22.3 3.4 14.0 1.0 0.021
α-Carotene (μmol/l) 0.08 0.00 0.06 0.01 0.09 0.00 <0.001
β-Carotene (μmol/l) 0.34 0.01 0.26 0.01 0.35 0.01 <0.001
Cryptoxanthin (μmol/l) 0.15 0.00 0.11 0.01 0.16 0.01 <0.001
Lutein/zeaxanthin (μmol/l) 0.37 0.01 0.33 0.02 0.37 0.01 0.015
Lycopene (μmol/l) 0.45 0.01 0.41 0.03 0.46 0.01 0.120
Total carotenoids (μmol/l) 1.38 0.03 1.17 0.06 1.42 0.03 <0.001
Se (nmol/l) 1.61 0.02 1.60 0.03 1.62 0.02 0.581
Vitamin C (mmol/l) 39.4 1.8 33.8 4.0 40.9 1.9 0.103
Vitamin E (μmol/l) 27.0 0.6 27.1 1.4 27.0 0.6 0.977
FEV1 (litres) 2.8 0.0 2.7 0.1 2.9 0.0 0.291
FVC (litres) 4.4 0.0 4.4 0.1 4.4 0.1 0.848
FEV1 (% predicted) 79.8 0.7 75.9 2.6 81.5 0.7 0.040
FVC (% predicted) 98.9 0.7 96.8 2.4 100.2 0.7 0.206
Men (%) 59.8 1.8 80.5 2.3 56.8 1.9 <0.001
Race or ethnicity
 White (%) 83.5 1.8 80.8 5.3 83.9 1.8 0.569
 African American (%) 7.5 0.9 16.1 5.0 6.8 0.9 0.070
 Mexican American (%) 2.2 0.4 1.4 0.7 2.2 0.4 0.247
 Other (%) 6.8 1.5 1.7 1.0 7.1 1.6 0.007
High-school graduate or higher (%) 74.0 2.6 45.0 4.2 77.1 2.9 <0.001
Smoking status
 Current smoker (%) 44.8 2.5 59.7 7.3 41.0 2.7 0.028
 Former smoker (%) 27.0 1.9 13.4 1.3 28.5 2.2 <0.001
 Never smoker (%) 28.2 2.5 26.9 7.5 30.5 2.8 0.676
Moderate-vigorous leisure-time physical activity (%) 45.0 2.4 39.8 7.8 46.4 2.9 0.429
Vitamin or mineral supplement use during past 30 d (%) 40.3 2.2 35.2 7.5 41.8 2.3 0.397













Ford et al. Page 17
Mortality status
Total (n 1492) Dead (n 629) Alive (n 863)
Mean SE Mean SE Mean SE P
C-reactive protein >3mg/l (%) 29.5 2.1 36.2 5.7 28.3 2.6 0.249
≥Good health status (%) 84.6 2.4 74.1 6.8 87.2 2.0 0.029
Diabetes (%) 5.3 0.7 5.6 0.8 4.2 0.8 0.212
History of myocardial infarction (%) 3.8 0.7 4.9 1.5 2.7 0.7 0.196
History of stroke (%) 1.7 0.4 3.0 1.5 1.2 0.4 0.230
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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Table 2
Associations between antioxidant concentrations and all-cause mortality among US adults aged 20 79 years 
with obstructive lung function, National Health and Nutrition Examination Survey III Linked Mortality File 
1988 94 to 2006
(Hazard ratios and 95 % confidence intervals)
Antioxidants* Hazard ratio 95 % CI P
Model 1†
 α-Carotene (μmol/l) 0.04 0.00, 0.33 0.004
 β-Carotene (μmol/l) 0.76 0.66, 0.88 <0.001
 Cryptoxanthin (μmol/l) 0.10 0.02, 0.46 0.004
 Lutein/zeaxanthin (μmol/l) 0.68 0.55, 0.85 0.001
 Lycopene (μmol/l) 0.71 0.61,0.81 <0.001
 Total carotenoids (μmol/l) 0.59 0.48, 0.73 <0.001
 Se (nmol/l) 0.77 0.41, 1.46 0.416
 Vitamin C (mmol/l) 0.88 0.84, 0.92 <0.001
 Vitamin E (μmol/l) 0.71 0.52, 0.98 0.039
Model 2‡
 α-Carotene (μmol/l) 0.12 0.02, 0.88 0.037
 β-Carotene (μmol/l) 0.83 0.70, 0.97 0.022
 Cryptoxanthin (μmol/l) 0.18 0.04, 0.77 0.022
 Lutein/zeaxanthin (μmol/l) 0.71 0.57, 0.89 0.004
 Lycopene (μmol/l) 0.75 0.64, 0.87 <0.001
 Total carotenoids (μmol/l) 0.65 0.51, 0.82 0.001
 Se (nmol/l) 0.83 0.44, 1.58 0.568
 Vitamin C (mmol/l) 0.91 0.87, 0.95 <0.001
 Vitamin E (μmol/l) 0.88 0.66, 1.19 0.412
Model 3§
 α-Carotene (μmol/l) 0.52 0.08, 3.56 0.499
 β-Carotene (μmol/l) 0.88 0.74, 1.04 0.133
 Cryptoxanthin (μmol/l) 0.36 0.10, 1.35 0.127
 Lutein/zeaxanthin (μmol/l) 0.80 0.64, 1.00 0.052
 Lycopene (μmol/l) 0.78 0.67, 0.91 0.002
 Total carotenoids (μmol/l) 0.74 0.58, 0.94 0.017
 Se (nmol/l) 1.00 0.55, 1.81 1.000
 Vitamin C (mmol/l) 0.94 0.90, 0.99 0.021
 Vitamin E (μmol/l) 0.98 0.73, 1.32 0.884
Model 4∥
 α-Carotene (μmol/l) 0.55 0.07, 4.34 0.566
 β-Carotene (μmol/l) 0.89 0.75, 1.07 0.210
 Cryptoxanthin (μmol/l) 0.42 0.12, 1.53 0.184
 Lutein/zeaxanthin (μmol/l) 0.81 0.62, 1.05 0.111
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Antioxidants* Hazard ratio 95 % CI P
 Lycopene (μmol/l) 0.80 0.69, 0.94 0.007
 Total carotenoids (μmol/l) 0.75 0.57, 1.00 0.051
 Se (nmol/l) 0.97 0.55, 1.74 0.930
 Vitamin C (mmol/l) 0.95 0.91, 1.00 0.042
 Vitamin E (μmol/l) 1.00 0.67, 1.49 0.989
Model 5¶
 α-Carotene (μmol/l) 0.62 0.08, 5.06 0.653
 β-Carotene (μmol/l) 0.92 0.78, 1.09 0.309
 Cryptoxanthin (μmol/l) 0.42 0.13, 1.39 0.151
 Lutein/zeaxanthin (μmol/l) 0.86 0.66, 1.11 0.235
 Lycopene (μmol/l) 0.80 0.67, 0.95 0.013
 Total carotenoids (μmol/l) 0.78 0.59, 1.03 0.075
 Se (nmol/l) 0.96 0.52, 1.79 0.900
 Vitamin C (mmol/l) 0.95 0.91, 1.00 0.046
 Vitamin E (μmol/l) 1.02 0.69, 1.50 0.922
*




Adjusted for variables in model 1 plus sex, race or ethnicity, and education.
§
Adjusted for variables in model 2 plus smoking status, alcohol consumption, leisure-time physical activity, and use of vitamin or mineral 
supplements.
∥
Adjusted for variables in model 3 plus systolic blood pressure, HDL-cholesterol, non-HDL-cholesterol, BMI, C-reactive protein and 
albumin:creatinine ratio.
¶
Adjusted for variables in model 4 plus health status, diabetes, history of myocar-dial infarction, and history of stroke.
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Table 3
Associations between antioxidant concentrations and cause-specific mortality among US adults aged 20–79 
years with obstructive lung function, National Health and Nutrition Examination Survey III Linked Mortality 
File 1988–94 to 2006*
(Adjusted hazard ratios and 95% confidence intervals)
Antioxidants Hazard ratio 95% CI P
Circulatory disease deaths (225 deaths)
 α-Carotene (μmol/l) 4.10 0.37, 45.19 0.243
 β-Carotene (μmol/l) 1.16 0.90, 1.51 0.245
 Cryptoxanthin (μmol/l) 1.12 0.38, 3.31 0.829
 Lutein/zeaxanthin (μmol/l) 1.04 0.72, 1.49 0.828
 Lycopene (μmol/l) 0.92 0.68, 1.23 0.560
 Total carotenoids (μmol/l) 1.11 0.74, 1.65 0.604
 Se (nmol/l) 1.04 0.32, 3.32 0.952
 Vitamin C (mmol/l) 1.04 0.94, 1.16 0.448
 Vitamin E (μmol/l) 1.14 0.62, 2.08 0.664
Cancer deaths (204 deaths)
 α-Carotene (μmol/l) 0.76 0.01, 41.30 0.889
 β-Carotene (μmol/l) 0.90 0.70, 1.17 0.433
 Cryptoxanthin (μmol/l) 0.20 0.01, 4.52 0.303
 Lutein/zeaxanthin (μmol/l) 0.88 0.57, 1.36 0.560
 Lycopene (μmol/l) 0.83 0.63, 1.09 0.176
 Total carotenoids (μmol/l) 0.77 0.51, 1.17 0.221
 Se (nmol/l) 0.93 0.41, 2.12 0.868
 Vitamin C (mmol/l) 0.85 0.78, 0.91 <0.001
 Vitamin E (μmol/l) 0.64 0.22, 1.88 0.412
Other deaths (200 deaths)
 α-Carotene (μmol/l) 0.06 0.00, 1.98 0.113
 β-Carotene (μmol/l) 0.76 0.58, 1.01 0.055
 Cryptoxanthin (μmol/l) 0.19 0.02, 1.51 0.113
 Lutein/zeaxanthin (μmol/l) 0.70 0.41, 1.17 0.171
 Lycopene (μmol/l) 0.70 0.51, 0.95 0.024
 Total carotenoids (μmol/l) 0.58 0.36, 0.93 0.024
 Se (nmol/l) 0.85 0.28, 2.58 0.775
 Vitamin C (mmol/l) 0.99 0.90, 1.10 0.919
 Vitamin E (μmol/l) 1.39 0.60, 3.23 0.435
*
Log transformations for the concentrations of β-carotene, lutein/zeaxanthin, lycopene, total carotenoids and vitamin E. Square root transformation 
for the concentration of vitamin C. Adjusted for age, sex, race or ethnicity, education, smoking status, alcohol consumption, leisure-time physical 
activity, use of vitamin or mineral supplements, systolic blood pressure, HDL-cholesterol, non-HDL-cholesterol, BMI, C-reactive protein, 
albumin:creatinine ratio, health status, diabetes, history of myocardial infarction and history of stroke. Estimates for each antioxidant were not 
adjusted for the concentrations of other antioxidants.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Br J Nutr. Author manuscript; available in PMC 2015 November 28.
